Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial.

ABSTRACT:

Background/objectives

Pancreatic ductal adeno carcinoma (PDAC) in its borderline resectable (BR) stage often limits the possibility of complete resection, currently the only potential path to a cure. Neoadjuvant chemotherapy seeks to downsize tumors, thereby increasing the chances of achieving an R0 resection. However, accurately predicting resectability following such treatment remains challenging. This study aims to identify and evaluate potential biomarkers that may improve preoperative assessment of tumor resectability during exploratory laparotomy, thereby minimizing the incidence of futile surgical interventions and their associated morbidity in patients with non-resectable malignancies.

Methods

We conducted a retrospective analysis of all patients who underwent explor

SUBMITTER: Schepp F 

PROVIDER: S-EPMC12490984 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature